Biotechnology to Taiwan

Trends and opportunities

The market

While the biotechnology sector is expanding in Taiwan, supported by strong government funding and private sector interest, there are some inherent weaknesses that provide opportunities.

Bridging this gap with Taiwan’s renowned manufacturing and capital investment capacity will result in the rapid development of this sector. Anti-cancer, anti-ageing, tissue culture, herbal medicine, medical devices, bio chip and informatics are hot topics in biotechnology development and Taiwan is looking for products and technology to develop new drugs/devices in these areas.

Leading pharmaceutical firms are aggressively seeking new product development, providing opportunities for Australian biotechnology investors and research companies.

The Taiwanese Government has recognised the importance of supporting the biotechnology industry and has backed this support with new initiatives such as the National Development Fund under the Executive Yuan. The Industry Development Bureau (IDB) under the Ministry of Economic Affairs (MOEA) reported that Taiwan’s biotechnology industry (including new biotech, pharmaceuticals and medical devices) value reached US$9.3 billion in 2013. The long-term objective is for Taiwan to hold three per cent of the world’s biotechnology market.

Due to the government’s strong commitment to biotechnology and the global investment supporting development in this area, the private sector has quickly developed interest in biotechnology. Taiwan’s Biotech industry increased from 1505 firms and 69 470 employees in 2012 to 1601 firms and 71 580 employees in 2013.

At the end of October 2014, there were 87 biotech companies registered in Taiwan Stock Exchange and Taiwan’s Over the Counter (OTC) market.

(Source: Industry Development Bureau, MOEA, 2015 Introduction to Biotechnology and Pharmaceutical Industries in Taiwan, Oct 2014)

Opportunities

The best opportunities for Australian biotechnology companies are in developing:

  • new dosage forms
  • protein drugs
  • animal and or plant derived products
  • modernised Chinese herbal medicines
  • intermediates of bulk pharmaceutical
  • clinical trials.

Three other areas of opportunity include new drug development, clinical trial cooperation and bio–informatics.

Competitive environment

There are a number of Australian companies already active in the market that are involved in a range of enterprises such as the development of anti-cancer compounds, toll manufacture of biomedical products and cochlear implant technology.

Major global pharmaceutical companies (such as GSK and Novartis) are quite active and have subsidiaries in Taiwan conducting sales and marketing and Research and Development (R&D) cooperation. Due to cost concerns, large pharmaceutical companies have moved their manufacturing bases out of Taiwan in the past few years.

Local pharmaceutical firms are mainly small with medium enterprises manufacturing generic and over-the-counter products. In order to capitalise on the recent growth in biotechnology, local pharmaceuticals firms are engaging in new areas of research: drug dosage, delivery development and Chinese herbal medicine.

Taiwan’s medical industry has garnered a strong reputation in recent years for manufacturing electronic medical equipment/devices. Some of the local medical manufacturers provide Original Equipment Manufacturer (OEM) services for international brands. The Taiwan Biotechnology Industry Association is actively promoting Taiwan’s medical equipment at international exhibitions.

Companies active in this industry include:

Pharmaceuticals

  • Yung Shin
  • China Chemical and Pharmaceutical Standard
  • Sin-tong
  • Sinphar.

Food

  • The President Group
  • Kingcar
  • AGV.

Chemical

  • Formosa Plastics Group
  • China Synthetic Rubber.

Government-owned enterprises

  • Taiwan Sugar
  • Taiwan Salt
  • Taiwan Tobacco and Wine Board
  • China Petroleum Corporation.

Emerging biotech companies include Taiwan Liposome (drug delivery system), Medigen (the partner of PI-88 anti-cancer drug from Australian Progen Pharmaceuticals) and Optimer Biotech (anti-cancer).

Other major players include China Steel, Lucky Cement, Yao Hua Glass and YFY Paper.

Tariffs, regulations and customs

The general tariff for generic drugs is zero per cent.

Industry standards

There are standards and qualification processes for projects to qualify for investment under the National Development Fund. These include:

  • Taiwan-based Asian operations, R&D or manufacturing centre.
  • Products manufactured must have USA or Patent Cooperation Treaty (PCT) patent protection.
  • Products manufactured must aim to comply with USA Food and Drug Administration (FDA) requirements.
  • Priority will be given to products that already have patents in Taiwan, to optimise allocation of investment resources.

FDA approval for new drugs will ensure quicker approval in Taiwan, although clinical trials will be necessary. For generic products, the manufacturers must be a Current Good Manufacturing Practice (cGMP) plant with a Free Sales Certificate issued by the highest health authority in the exporting country e.g. Therapeutic Goods Administration (TGA) in Australia.

Marketing your products and services

Market entry

There are a number of important market entry considerations as biotechnology is still a high-risk venture. Primarily, investors or prospective local partners in Taiwan need well prepared proposals and sound business plans to conduct evaluations. It is also important to monitor government policies closely and to form contacts.

For Australian companies seeking biotechnology joint-venture partners:

  • Understand government polices (particularly if interested in the National Development Fund).
  • Get to know the profiles of partners – venture capital firms or current players in the bio–pharmaceutical sector.
  • Present to the key people from the right companies.
  • Follow-up diligently on return to Australia.

For seeking trade partners:

  • Understand the market potential.
  • Know the import regulations and requirements.
  • Identify and work with an agent for product registration and marketing.

Australian companies should target and market directly to key contacts in Taiwan. Be well prepared with detailed documentation and business plans. Australian exporters and companies seeking joint venture companies or alliances should take advantage of the following:

  • Taiwan’s desire to be an international (or regional) oriented biotechnology world player, not a domestic one.
  • Australia’s reputation for world-leading research and connections in world leading biotechnology fields
  • Current needs and sector interest e.g. anti-cancer, anti-ageing, tissue culture, herbal medicine and bio-informatics.
  • Meeting Taiwanese business executives and investors by visiting key biotechnology events around the world.

If interested in exporting biotechnology to Taiwan, it is important to prepare a quality company website. Many of the major biotechnology start-up companies are located in the major science parks and all companies have high speed internet access.

Distribution channels

Most prescription type drugs are obtained from the hospital pharmacy or alternatively from the dispensary at the doctor’s surgery. Retail pharmacies in Taiwan carry prescription-type drugs and also offer an extensive range of over-the-counter pharmaceuticals such as analgesics and stomach medicines.

Most major foreign global pharmaceutical companies have Taiwanese agents who will arrange import documentation, hold stock and distribute to hospitals and individual doctor’s surgeries. Mergers and acquisitions within global pharmaceutical and veterinary companies have meant a rationalisation of agents in the market and there are a now a number of well-established agents who are eagerly looking for new products to distribute.

It is critical that any Australian company clearly establishes the end user for their products and then examines potential in the distribution chain. This will allow the Australian company the opportunity to maximise market potential. The possibility of multi-distributors here handling different product lines should not be overlooked.

If you attempt to sell products over the internet without a license issued by the Ministry of Health and Welfare in Taiwan, these drugs will be regarded as illegal imports and may not be distributed.

Links and industry contacts

Biotechnology–related resources

The Biotechnology and Pharmaceutical Industries Program Office
Development Centre for Biotechnology
Industrial Development Bureau, MOEA
Industrial Technology Research Institute
Taiwan Biotechnology Takeoff Diamond Action Plan

Government, business and trade resources

Ministry of Economic Affairs
Ministry of Science and Technology

Media

China Post
Taipei Times
Taiwan Headlines

Please note: This list of websites and resources is not definitive. Inclusion in this list does not imply endorsement by Austrade. The information provided is a guide only. The content is for information and carries no warranty; as such, the addressee must exercise their own discretion in its use. Australia’s anti-bribery laws apply overseas and Austrade will not provide business related services to any party who breaches the law and will report credible evidence of any breach. For further information, please see foreign bribery information and awareness pack.

Contact details

The Australian Trade and Investment Commission – Austrade – contributes to Australia's economic prosperity by helping Australian businesses, education institutions, tourism operators, governments and citizens as they:

  • develop international markets
  • win productive foreign direct investment
  • promote international education
  • strengthen Australia's tourism industry
  • seek consular and passport services.

Working in partnership with Australian state and territory governments, Austrade provides information and advice that can help Australian companies reduce the time, cost and risk of exporting. We also administer the Export Market Development Grant Scheme and offer a range of services to Australian exporters in growth and emerging markets.